Clinical Trial Update: A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis [Phase 1]

View source ↗

Summary

This is a completed Phase 1 study evaluating the safety of GSK2398852 when co-administered with GSK2315698 in patients with systemic amyloidosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloidosis
• Systemic Amyloidosis

Drugs mentioned

• GSK2315698
• GSK2398852

Snippet

Sponsor: GlaxoSmithKline | Conditions: Amyloidosis | Phase 1 | Status: COMPLETED